Overview
- The peer-reviewed study, published in Nature Medicine with results also presented at AHA Scientific Sessions 2025, analyzed Medicare, Optum Clinformatics, and Merative MarketScan claims covering routine U.S. care.
- Semaglutide lowered one-year risk of myocardial infarction or stroke versus sitagliptin, showing an approximately 18% relative reduction (HR 0.82; 95% CI, 0.74–0.91).
- Tirzepatide demonstrated cardiovascular effectiveness versus dulaglutide with a lower major adverse cardiovascular event rate (HR 0.87; 95% CI, 0.75–1.01).
- In a head-to-head comparison, tirzepatide and semaglutide produced equivalent cardiovascular outcomes (HR 1.06; 95% CI, 0.95–1.18), indicating no clear advantage for either agent.
- Trial-emulation benchmarks aligned closely with randomized data, benefits appeared early and likely extend beyond weight loss, and investigators cautioned about residual confounding for all-cause mortality in claims-based analyses.